Pharma B2C

The industry presents an attractive investment opportunity due to its stable growth trajectory, improving pricing power, and favorable currency dynamics. However, investors should remain cautious of potential margin pressures stemming from rising input costs and pricing challenges in key markets.

The Indian pharmaceutical sector is currently experiencing an expansion phase, driven by favorable currency depreciation and a robust pipeline of innovative products and biosimilars. With a historical CAGR of 10.65% and a forecast CAGR of nearly 6%, the industry demonstrates strong growth potential, particularly for companies with significant export exposure. The business economics reflect stable margins, although a slight decline is anticipated due to rising input costs and pricing pressures in key markets. Despite these challenges, the overall sentiment remains positive, supported by resilient demand in chronic therapies and a favorable regulatory environment. From an investment perspective, the sector is attractive due to its stable growth trajectory and improving pricing power, although investors should be mindful of the potential headwinds that could impact profitability.